Progenics Pharmaceutical (PGNX) Resumes Trading Up 7% Upon FDA Approval
Tweet Send to a Friend
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) has resumed trading up 7.6% after the company and partner Salix Pharmaceuticals, Ltd ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
